Oral therapy for multiple myeloma: ixazomib arriving soon.
Moreau P. Blood. 2014 Aug 14;124(7):986-7. doi: 10.1182/blood-2014-06-581611.

A multicenter, open-label phase II study of recombinant CPT (circularly permuted TRAIL) plus thalidomide in patients with relapsed and/or refractory multiple myeloma.
Geng C et al. Am J Hematol. 2014 Aug 4. doi: 10.1002/ajh.23822. [Epub ahead of print].

Novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma: Phase 1 study results.
Spencer A et al. Blood. 2014 Jul 29. pii: blood-2014-03-559963. [Epub ahead of print].